Clinical Trials Browser

Phase 2 × poly ICLC × 90 days × Clear all

NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms